ARID1A gene mutation in ovarian and endometrial cancers (Review)

Takashi Takeda, Kouji Banno, Ryuichiro Okawa, Megumi Yanokura, Moito Iijima, Haruko Iriekunitomi, Kanako Nakamura, Miho Iida, Masataka Adachi, Kiyoko Umene, Yuya Nogami, Kenta Masuda, Yusuke Kobayashi, Eiichiro Tominaga, Daisuke Aoki

Research output: Contribution to journalArticle

52 Citations (Scopus)

Abstract

The ATrich interacting domaincontaining protein 1A gene (ARID1A) encodes ARID1A, a member of the SWI/SNF chromatin remodeling complex. Mutation of ARID1A induces changes in expression of multiple genes (CDKN1A, SMAD3, MLH1 and PIK3IP1) via chromatin remodeling dysfunction, contributes to carcinogenesis, and has been shown to cause transformation of cells in association with the PI3K/AKT pathway. Information on ARID1A has emerged from comprehensive genome wide analyses with next generation sequencers. ARID1A mutations have been found in various types of cancer and occur at high frequency in endometriosis associated ovarian cancer including clear cell adenocarcinoma and endometrioid adenocarcinoma, and also occur at endometrial cancer especially in endometrioid adenocarcinoma. It has also been suggested that ARID1A mutation occurs at the early stage of canceration from endometriosis to endometriosis associated carcinoma in ovarian cancer and also from atypical endometrial hyperplasia to endometrioid adenocarcinoma in endometrial cancer. Therefore, development of a screening method that can detect mutations of ARID1A and activation of the PI3K/AKT pathway might enable early diagnosis of endometriosis associated ovarian cancers and endometrial cancers. Important results may also emerge from a current clinical trial examining a multidrug regimen of temsirolimus a small molecule inhibitor of the PI3K/AKT pathway for treatment of advanced ovarian clear cell adenocarcinoma with ARID1A mutation and PI3K/AKT pathway activation. Also administration of sorafenib, a multikinase inhibitor, can inhibit cancer proliferation with PIK3CA mutation and resistance to mTOR inhibitors and GSK126, a molecular targeted drug can inhibit proliferation of ARID1A mutated ovarian clear cell adenocarcinoma cells by targeting and inhibiting EZH2. Further studies are needed to determine the mechanism of chromatin remodeling dysregulation initiated by ARID1A mutation, to develop methods for early diagnosis to investigate new cancer therapy targeting ARID1A, and to examine the involvement of ARID1A mutations in development survival and progression of cancer cells.

Original languageEnglish
Pages (from-to)607-613
Number of pages7
JournalOncology Reports
Volume35
Issue number2
DOIs
Publication statusPublished - 2016 Feb 1

Fingerprint

Endometrial Neoplasms
Ovarian Neoplasms
Mutation
Genes
Proteins
Clear Cell Adenocarcinoma
Endometriosis
Endometrioid Carcinoma
Phosphatidylinositol 3-Kinases
Chromatin Assembly and Disassembly
Early Diagnosis
Neoplasms
Endometrial Hyperplasia
Transcriptional Activation
Carcinogenesis
Clinical Trials
Genome
Carcinoma
Gene Expression

Keywords

  • ARID1A
  • Chromatin remodeling
  • Ovarian cancer endometrial cancer
  • PI3K/AKT

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Takeda, T., Banno, K., Okawa, R., Yanokura, M., Iijima, M., Iriekunitomi, H., ... Aoki, D. (2016). ARID1A gene mutation in ovarian and endometrial cancers (Review). Oncology Reports, 35(2), 607-613. https://doi.org/10.3892/or.2015.4421

ARID1A gene mutation in ovarian and endometrial cancers (Review). / Takeda, Takashi; Banno, Kouji; Okawa, Ryuichiro; Yanokura, Megumi; Iijima, Moito; Iriekunitomi, Haruko; Nakamura, Kanako; Iida, Miho; Adachi, Masataka; Umene, Kiyoko; Nogami, Yuya; Masuda, Kenta; Kobayashi, Yusuke; Tominaga, Eiichiro; Aoki, Daisuke.

In: Oncology Reports, Vol. 35, No. 2, 01.02.2016, p. 607-613.

Research output: Contribution to journalArticle

Takeda, T, Banno, K, Okawa, R, Yanokura, M, Iijima, M, Iriekunitomi, H, Nakamura, K, Iida, M, Adachi, M, Umene, K, Nogami, Y, Masuda, K, Kobayashi, Y, Tominaga, E & Aoki, D 2016, 'ARID1A gene mutation in ovarian and endometrial cancers (Review)', Oncology Reports, vol. 35, no. 2, pp. 607-613. https://doi.org/10.3892/or.2015.4421
Takeda T, Banno K, Okawa R, Yanokura M, Iijima M, Iriekunitomi H et al. ARID1A gene mutation in ovarian and endometrial cancers (Review). Oncology Reports. 2016 Feb 1;35(2):607-613. https://doi.org/10.3892/or.2015.4421
Takeda, Takashi ; Banno, Kouji ; Okawa, Ryuichiro ; Yanokura, Megumi ; Iijima, Moito ; Iriekunitomi, Haruko ; Nakamura, Kanako ; Iida, Miho ; Adachi, Masataka ; Umene, Kiyoko ; Nogami, Yuya ; Masuda, Kenta ; Kobayashi, Yusuke ; Tominaga, Eiichiro ; Aoki, Daisuke. / ARID1A gene mutation in ovarian and endometrial cancers (Review). In: Oncology Reports. 2016 ; Vol. 35, No. 2. pp. 607-613.
@article{2673861cf97f4442a1058dc1a14b83a3,
title = "ARID1A gene mutation in ovarian and endometrial cancers (Review)",
abstract = "The ATrich interacting domaincontaining protein 1A gene (ARID1A) encodes ARID1A, a member of the SWI/SNF chromatin remodeling complex. Mutation of ARID1A induces changes in expression of multiple genes (CDKN1A, SMAD3, MLH1 and PIK3IP1) via chromatin remodeling dysfunction, contributes to carcinogenesis, and has been shown to cause transformation of cells in association with the PI3K/AKT pathway. Information on ARID1A has emerged from comprehensive genome wide analyses with next generation sequencers. ARID1A mutations have been found in various types of cancer and occur at high frequency in endometriosis associated ovarian cancer including clear cell adenocarcinoma and endometrioid adenocarcinoma, and also occur at endometrial cancer especially in endometrioid adenocarcinoma. It has also been suggested that ARID1A mutation occurs at the early stage of canceration from endometriosis to endometriosis associated carcinoma in ovarian cancer and also from atypical endometrial hyperplasia to endometrioid adenocarcinoma in endometrial cancer. Therefore, development of a screening method that can detect mutations of ARID1A and activation of the PI3K/AKT pathway might enable early diagnosis of endometriosis associated ovarian cancers and endometrial cancers. Important results may also emerge from a current clinical trial examining a multidrug regimen of temsirolimus a small molecule inhibitor of the PI3K/AKT pathway for treatment of advanced ovarian clear cell adenocarcinoma with ARID1A mutation and PI3K/AKT pathway activation. Also administration of sorafenib, a multikinase inhibitor, can inhibit cancer proliferation with PIK3CA mutation and resistance to mTOR inhibitors and GSK126, a molecular targeted drug can inhibit proliferation of ARID1A mutated ovarian clear cell adenocarcinoma cells by targeting and inhibiting EZH2. Further studies are needed to determine the mechanism of chromatin remodeling dysregulation initiated by ARID1A mutation, to develop methods for early diagnosis to investigate new cancer therapy targeting ARID1A, and to examine the involvement of ARID1A mutations in development survival and progression of cancer cells.",
keywords = "ARID1A, Chromatin remodeling, Ovarian cancer endometrial cancer, PI3K/AKT",
author = "Takashi Takeda and Kouji Banno and Ryuichiro Okawa and Megumi Yanokura and Moito Iijima and Haruko Iriekunitomi and Kanako Nakamura and Miho Iida and Masataka Adachi and Kiyoko Umene and Yuya Nogami and Kenta Masuda and Yusuke Kobayashi and Eiichiro Tominaga and Daisuke Aoki",
year = "2016",
month = "2",
day = "1",
doi = "10.3892/or.2015.4421",
language = "English",
volume = "35",
pages = "607--613",
journal = "Oncology Reports",
issn = "1021-335X",
publisher = "Spandidos Publications",
number = "2",

}

TY - JOUR

T1 - ARID1A gene mutation in ovarian and endometrial cancers (Review)

AU - Takeda, Takashi

AU - Banno, Kouji

AU - Okawa, Ryuichiro

AU - Yanokura, Megumi

AU - Iijima, Moito

AU - Iriekunitomi, Haruko

AU - Nakamura, Kanako

AU - Iida, Miho

AU - Adachi, Masataka

AU - Umene, Kiyoko

AU - Nogami, Yuya

AU - Masuda, Kenta

AU - Kobayashi, Yusuke

AU - Tominaga, Eiichiro

AU - Aoki, Daisuke

PY - 2016/2/1

Y1 - 2016/2/1

N2 - The ATrich interacting domaincontaining protein 1A gene (ARID1A) encodes ARID1A, a member of the SWI/SNF chromatin remodeling complex. Mutation of ARID1A induces changes in expression of multiple genes (CDKN1A, SMAD3, MLH1 and PIK3IP1) via chromatin remodeling dysfunction, contributes to carcinogenesis, and has been shown to cause transformation of cells in association with the PI3K/AKT pathway. Information on ARID1A has emerged from comprehensive genome wide analyses with next generation sequencers. ARID1A mutations have been found in various types of cancer and occur at high frequency in endometriosis associated ovarian cancer including clear cell adenocarcinoma and endometrioid adenocarcinoma, and also occur at endometrial cancer especially in endometrioid adenocarcinoma. It has also been suggested that ARID1A mutation occurs at the early stage of canceration from endometriosis to endometriosis associated carcinoma in ovarian cancer and also from atypical endometrial hyperplasia to endometrioid adenocarcinoma in endometrial cancer. Therefore, development of a screening method that can detect mutations of ARID1A and activation of the PI3K/AKT pathway might enable early diagnosis of endometriosis associated ovarian cancers and endometrial cancers. Important results may also emerge from a current clinical trial examining a multidrug regimen of temsirolimus a small molecule inhibitor of the PI3K/AKT pathway for treatment of advanced ovarian clear cell adenocarcinoma with ARID1A mutation and PI3K/AKT pathway activation. Also administration of sorafenib, a multikinase inhibitor, can inhibit cancer proliferation with PIK3CA mutation and resistance to mTOR inhibitors and GSK126, a molecular targeted drug can inhibit proliferation of ARID1A mutated ovarian clear cell adenocarcinoma cells by targeting and inhibiting EZH2. Further studies are needed to determine the mechanism of chromatin remodeling dysregulation initiated by ARID1A mutation, to develop methods for early diagnosis to investigate new cancer therapy targeting ARID1A, and to examine the involvement of ARID1A mutations in development survival and progression of cancer cells.

AB - The ATrich interacting domaincontaining protein 1A gene (ARID1A) encodes ARID1A, a member of the SWI/SNF chromatin remodeling complex. Mutation of ARID1A induces changes in expression of multiple genes (CDKN1A, SMAD3, MLH1 and PIK3IP1) via chromatin remodeling dysfunction, contributes to carcinogenesis, and has been shown to cause transformation of cells in association with the PI3K/AKT pathway. Information on ARID1A has emerged from comprehensive genome wide analyses with next generation sequencers. ARID1A mutations have been found in various types of cancer and occur at high frequency in endometriosis associated ovarian cancer including clear cell adenocarcinoma and endometrioid adenocarcinoma, and also occur at endometrial cancer especially in endometrioid adenocarcinoma. It has also been suggested that ARID1A mutation occurs at the early stage of canceration from endometriosis to endometriosis associated carcinoma in ovarian cancer and also from atypical endometrial hyperplasia to endometrioid adenocarcinoma in endometrial cancer. Therefore, development of a screening method that can detect mutations of ARID1A and activation of the PI3K/AKT pathway might enable early diagnosis of endometriosis associated ovarian cancers and endometrial cancers. Important results may also emerge from a current clinical trial examining a multidrug regimen of temsirolimus a small molecule inhibitor of the PI3K/AKT pathway for treatment of advanced ovarian clear cell adenocarcinoma with ARID1A mutation and PI3K/AKT pathway activation. Also administration of sorafenib, a multikinase inhibitor, can inhibit cancer proliferation with PIK3CA mutation and resistance to mTOR inhibitors and GSK126, a molecular targeted drug can inhibit proliferation of ARID1A mutated ovarian clear cell adenocarcinoma cells by targeting and inhibiting EZH2. Further studies are needed to determine the mechanism of chromatin remodeling dysregulation initiated by ARID1A mutation, to develop methods for early diagnosis to investigate new cancer therapy targeting ARID1A, and to examine the involvement of ARID1A mutations in development survival and progression of cancer cells.

KW - ARID1A

KW - Chromatin remodeling

KW - Ovarian cancer endometrial cancer

KW - PI3K/AKT

UR - http://www.scopus.com/inward/record.url?scp=84954305411&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84954305411&partnerID=8YFLogxK

U2 - 10.3892/or.2015.4421

DO - 10.3892/or.2015.4421

M3 - Article

C2 - 26572704

AN - SCOPUS:84954305411

VL - 35

SP - 607

EP - 613

JO - Oncology Reports

JF - Oncology Reports

SN - 1021-335X

IS - 2

ER -